Clinical Trial Update: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia [Phase 3]

View source ↗

Summary

Phase 3 open-label extension study evaluating fostamatinib disodium for warm antibody autoimmune hemolytic anemia is enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Antibody Autoimmune Hemolytic Anemia

Drugs mentioned

• Fostamatinib disodium (fostamatinib disodium)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | Status: ENROLLING_BY_INVITATION